Subgroup Analyses of a Phase 3, Multicenter, Double-Blind, Placebo-Controlled Trial of Lenvatinib (E7080) in Patients with 131I-Refractory Differentiated Thyroid Cancer
Publication/Presentation Date
9-2014
Volume
25
Issue
4
First Page
355
Last Page
355
Published In/Presented At
Disciplines
Medicine and Health Sciences
Department(s)
Hematology-Medical Oncology Division
Document Type
Article
COinS